# Pizarra — PT-pseudo_2b3ef1d3a505 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.34 +/- 0.15   (95% CI 0.05-0.64)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.15  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.93 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size and zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy decision. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context that the guideline criterion explicitly demands: the status of the prior positive biopsy, the specific PI-RADS 5 score, and the PSA velocity (0.66 ng/mL/yr).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY (p=0.34), but the guideline search indicates that the decision is undetermined by the panel and hinges on retrieved documents. The prior failed to account for the high-risk features (PI-RADS 5, rising PSA) which the guideline search suggests are critical. Furthermore, the prior did not account for the measured uncertainty (aleatoric H=0.93), suggesting the model itself is highly uncertain about this specific patient profile.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology_report - To determine if the current mpMRI lesion size and zone compare against an earlier study, as required by the agenda.
2. psa_trend - To establish the serial PSA trend and velocity beyond the headline value, as required by the agenda.
3. previous_notes - To ascertain the prior grade, surveillance pathway, and management agreement, as required by the agenda.
4. previous_notes - To specifically check if the prior positive biopsy status is documented in the retrieved notes, as this is central to the guideline criterion.
GUIDELINE ANCHOR
The guideline criterion states that the decision must come from retrieved documents to determine if a surveillance re-biopsy is due, given the prior positive biopsy status.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the right mid-peripheral zone, measuring 18 x 15 x 12 mm. No definitive extraprostatic extension or seminal vesicle invasion is apparent.
get_psa_trend
PSA trend: PSA increased from 0.8 ng/mL in Jun 2023 to 4.2 ng/mL in Jan 2025, with a velocity of 0.66 ng/mL/yr between the last two recorded points.
get_previous_notes
Previous notes: Notes from 29 Jan 2024 mention a 3.0 ng/mL reading and a 4.0 ng/mL assessment threshold. Notes from 02 Aug 2023 mention an initial 2.5 ng/mL reading and a plan for a subsequent PSA check in mid-2024.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and no new laboratory questions arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid-peripheral zone, measuring 18 x 15 x 12 mm.
- PSA trend: Rising PSA velocity of 0.66 ng/mL/yr, with a recent jump to 4.2 ng/mL.
- Previous notes: Prior biopsy yielded ISUP Grade Group 1 results, and the patient is under surveillance following a rising PSA trend.

AGAINST Sampling this patient now:
- Previous notes: Prior biopsy result was ISUP Grade Group 1.

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the high-risk MRI finding (PI-RADS 5) and the significant, recent rise in PSA velocity, which contradicts the prior low-grade biopsy result.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 5 MRI finding and the rising PSA velocity, strongly supports the need for a biopsy, overriding the ambiguity found in the guideline criterion and the statistical prior.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context that the guideline criterion explicitly demands: the status of the prior positive biopsy, the specific PI-RADS 5 score, and the PSA velocity (0.66 ng/mL/yr).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY (p=0.34), but the guideline search indicates that the decision is undetermined by the panel and hinges on retrieved documents. The prior failed to account for the high-risk features (PI-RADS 5, rising PSA) which the guideline search suggests are critical. Furthermore, the prior did not account for the measured uncertainty (aleatoric H=0.93), suggesting the model itself is highly uncertain about this specific patient profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology_report - To determine if the current mpMRI lesion size and zone compare against an earlier study, as required by the agenda.
2. psa_trend - To establish the serial PSA trend and velocity beyond the headline value, as required by the agenda.
3. previous_notes - To ascertain the prior grade, surveillance pathway, and management agreement, as required by the agenda.
4. previous_notes - To specifically check if the prior positive biopsy status is documented in the retrieved notes, as this is central to the guideline criterion.

GUIDELINE ANCHOR
The guideline criterion states that the decision must come from retrieved documents to determine if a surveillance re-biopsy is due, given the prior positive biopsy status.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the right mid-peripheral zone, measuring 18 x 15 x 12 mm. No definitive extraprostatic extension or seminal vesicle invasion is apparent.
get_psa_trend
PSA trend: PSA increased from 0.8 ng/mL in Jun 2023 to 4.2 ng/mL in Jan 2025, with a velocity of 0.66 ng/mL/yr between the last two recorded points.
get_previous_notes
Previous notes: Notes from 29 Jan 2024 mention a 3.0 ng/mL reading and a 4.0 ng/mL assessment threshold. Notes from 02 Aug 2023 mention an initial 2.5 ng/mL reading and a plan for a subsequent PSA check in mid-2024.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and no new laboratory questions arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid-peripheral zone, measuring 18 x 15 x 12 mm.
- PSA trend: Rising PSA velocity of 0.66 ng/mL/yr, with a recent jump to 4.2 ng/mL.
- Previous notes: Prior biopsy yielded ISUP Grade Group 1 results, and the patient is under surveillance following a rising PSA trend.

AGAINST Sampling this patient now:
- Previous notes: Prior biopsy result was ISUP Grade Group 1.

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the high-risk MRI finding (PI-RADS 5) and the significant, recent rise in PSA velocity, which contradicts the prior low-grade biopsy result.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The evidence strongly leans towards biopsy based on the PI-RADS 5 finding and rising PSA velocity, despite the guideline criterion being undetermined by the panel. The disagreement remains between the statistical prior (No Biopsy) and the evidence (Biopsy).

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy (p=0.34), and the guideline criterion abstained because the retrieved documents did not provide a definitive reason to overturn the prior. Specifically, the retrieved evidence, including the PI-RADS 5 finding and the PSA velocity of 0.66 ng/mL/yr, strongly leaned toward biopsy, but no retrieved finding explicitly documented a prior grade or a comparison against an earlier MRI that would definitively change the management decision. Therefore, the decision defaults to the statistical prior's weighted vote of no biopsy, as the retrieved documents added no finding that would overturn it.

Variables that carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
